BIOCON

Biocon Ltd., Asia's premier biopharmaceutical company, is committed to ensure a global right to healthcare
by addressing the worldwide need for safe, effective and affordable biotherapeutics. We have harnessed the
power of biotechnology through affordable innovation to enhance access to new and differentiated therapies
for diseases that are chronic, where medical needs are largely unmet.

The Company is a pioneer in bringing the benefit of high quality, yet affordable, novel biologics and
biosimilars to patients in India and other emerging markets. Today, we are India's largest and fully-
integrated biopharmaceutical company that develops, manufactures and supplies advanced, life-saving
biopharmaceuticals for diabetes, cancer and autoimmune conditions at price points that make them
affordable and thus accessible.

As an innovation-led organization focused on providing affordable access, we have leveraged our inherent
strengths in advanced science to develop, manufacture and deliver a rich portfolio of small molecules APIs &
formulations and complex biologics - both novels and biosimilars - including monoclonal antibodies (MAbs),
rh-Insulin and insulin analogs.

Our global scale capacities for manufacturing high quality, affordable biologics have positioned us as the
world's fourth largest insulins producer, enabling us to address the growing needs of diabetes patients
across the globe. As one of the leading oncology companies in India, we have brought safe, efficacious and
affordable medicines for cancer to cater to the needs of patients, caregivers and medical practitioners in the
country.

As India's largest domestic branded biologics company, we have taken key products like INSUGEN (rh-
insulin), BASALOG(Glargine), CANMAb (Trastuzumab), BIOMAb-EGFR(Nimotuzumab) and
ALZUMAb (Itolizumab), a first in class anti-CD6 monoclonal antibody, from discovery to
commercialization.

Seeking Global Leadership

Our value proposition, built around differentiation and scale, has enabled us to seek global leadership to
provide access to affordable biopharmaceuticals for patients, partners and healthcare systems across the
globe. Our patient-centric approach and commitment to world-class quality have earned the trust of
partners, doctors, patients, care givers and healthcare ecosystems around the world. Our aim over the next
10 years is to provide our insulin products to 'one in five' diabetes patients in need of insulin-based therapy
anywhere in the world. Biocon is poised to emerge as a relevant global enterprise, delivering cutting-edge
innovation that is affordable, available and accessible.

Strategic Capabilities
To address the global healthcare challenges associated with non-communicable diseases such as cancer and
diabetes we have invested in cutting-edge science, global manufacturing scale and key international
collaborations. In this endeavor, we have created a highly cross-functional matrix focused on products,
processes and people to reliably and consistently develop and deliver differentiated products. We have
consistently been among the pharma companies in India with the highest investments in research and
development. We have made long-term investments in creating 'best-in-class' complex biologics
manufacturing capabilities. We have rapidly moved up the pharmaceutical value chain from small molecules
to recombinant proteins to antibodies. We have leveraged India's value advantage of unmatched scientific
talent and cost-competitive manufacturing to deliver scale, speed and quality. Over time, we have emerged
as a highly innovative biopharmaceuticals enterprise that has benefited millions of patients in over 100
countries.

Commitment to Quality
Our state-of-the-art manufacturing facilities - both mammalian and microbial - designed to conform to the
most stringent cGMP guidelines, comply with international regulatory standards and meet client
requirements worldwide. Our commitment to high cGMP standards and quality compliance helped us
maintain a strong track record in regulatory inspections with no critical observations. We have received
cGMP approvals from over 25 international regulatory agencies, including those from US, EU, Japan, France,
Brazil, Mexico, Turkey and GCC among others.
Overseas Facility
We have successfully commissioned our first overseas manufacturing facility at BioXcell, a biotechnology
park in Johor, Malaysia. This greenfield integrated insulins manufacturing facility, one of Asia's largest, will
cater to our global ambitions in the insulins space. The facility has received local cGMP certification from the
National Pharmaceutical Control Bureau, Malaysia.

Biosimilars Pipeline

Click here to enlarge

Generic Insulins Pipeline

Click here to enlarge

Robust Biosimilars Portfolio

Biocon has among the largest and most diversified portfolios of biosimilars in advanced stages of
development. Having made biosimilars available to patients in India and other emerging markets, Biocon is
the first Indian company to launch biosimilar Insulin Glargine in Japan, one of the world's most stringently
regulated markets. We will address the unfolding global biosimilars opportunity through a high-value
portfolio comprises six biosimilars for oncology and autoimmune indications, three insulin analogs and
generic rh-insulin. Collectively, these represent a global addressable market opportunity of over USD 70
billion at current reference product pricing. More importantly, the portfolio addresses many critical chronic
diseases such as diabetes, cancer and autoimmune disorders. Biocon, in collaboration with its global partner
Mylan, has made significant progress in advancing our key assets through global clinical trials. Overall, we
are well positioned to be amongst the first wave of companies to address the biosimilars opportunity globally
by leveraging our strong development capabilities, world-class manufacturing facilities, unblemished track
record of quality compliance and strong global and regional partnerships.

Novel Assets Under Clinical Development

 Click here to enlarge

Credible Biopharma Innovator

We have leveraged our affordable innovation model to develop and commercialize novel therapies for cancer
and autoimmune conditions. We have delivered to the Indian patient BIOMAb-EGFR , a novel biologic for
cancer, and ALZUMAb(Itolizumab), our second novel biologic for treating chronic plaque psoriasis. We are
now harnessing our capabilities in novel drug discovery research to advance an exciting oral insulin, Insulin
Tregopil, through the clinics. We are also making progress on Itolizumab, the world's only clinically validated
anti-CD6 targeting molecule, which we want to take to a global population. We are also exploring the
breakthrough potential of immuno-oncology to develop patient-friendly therapies against malignant
tumours. Our novel programs span a wide range of platforms and products from conventional peptides &
MAbs to novel fusion MAbs and small interfering RNA (siRNA) based therapeutics.

Research Services
We also providing integrated contract research and manufacturing services to leading global pharmaceutical
and biotechnology companies through our subsidiary Syngene. With over 2,500 research scientists and a
laboratory base over 900,000 square feet, Syngene services a diverse range of over 250 clients, including 8
of the Top 10 global pharma majors.

Consistent Value Creator

Biocon has been creating long-term value for its shareholders with the market capitalisation of the Company
having multiplied almost four times since its debut on the bourses in 2004. Biocon was only the second
Indian company to cross the USD 1 billion market capitalisation milestone on the first day of listing. In 2015,
the successful IPO of Biocon's research services subsidiary Syngene unlocked immense value for
shareholders. Syngene's market capitalization crossed the USD 1 billion mark within a week of listing.

Reputed Biotech Employer

We have built an employee-friendly environment for our gender-diverse workforce that is comparable to the
best in the world. This has been validated by our position among the Top 20 Best Employers in the Biotech
Industry as ranked by the prestigious Science magazine.

Conscientious Corporate Citizen

Our underlying ethos of access and affordability goes beyond our business. It represents the focus of the
initiatives by Biocon Foundation, our Corporate Social Responsibility (CSR) wing. For over a decade now,
Biocon Foundation has been promoting social and economic inclusion through healthcare, educational, and
community development programs. These programs address the 'Right to Health', the 'Right to Education'
and the 'Right to Sanitation' of the economically weaker sections of Indian society. WHO India recently
recognized Biocon Foundation as a 'Public Health Champion' for providing sustainable solutions in the area of
public health.

Biocon Academy spearheads our CSR initiatives in addressing the skill deficit in the Indian biotechnology
industry by developing high-end talent through advanced learning and industrial training. Established as a
Centre of Excellence for Advanced Learning in Biosciences in 2014, Biocon Academy leverages the rich
industry experience of Biocon and subject matter expertise of international education partners such as Keck
Graduate Institute of Claremont, California (US) to bridge the industry-academia gap.